HYPERRAB

This brand name is authorized in Canada, Hong Kong, Singapore, United States

Active ingredients

The drug HYPERRAB contains one active pharmaceutical ingredient (API):

1 Human rabies immunoglobulin
UNII 95F619ATQ2 - HUMAN RABIES VIRUS IMMUNE GLOBULIN

Human rabies immunoglobulin contains mainly immunoglobulin G (IgG) with a specifically high content of antibodies against rabies virus. Human Rabies Immunoglobulin must always be used in combination with a rabies vaccine.

Read about Human rabies immunoglobulin

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
HYPERRAB Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
J06BB05 Rabies immunoglobulin J Antiinfectives for systemic use → J06 Immune sera and immunoglobulins → J06B Immunoglobulins → J06BB Specific immunoglobulins
Discover more medicines within J06BB05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: CA Health Products and Food Branch Identifier(s): 02486571
Country: HK Department of Health Drug Office Identifier(s): 54931
Country: SG Health Sciences Authority Identifier(s): 09657P
Country: US FDA, National Drug Code Identifier(s): 13533-318, 13533-618

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.